FAHIM QURESHI: Open Payments
NPI 1093785297 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,622 in 123 payments from 13 companies in 2025. Trend: 2023 $631 · 2024 $1,122 · 2025 $2,622
Food & beverage: $2,523Education: $100
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $385 |
| Otsuka America Pharmaceutical, Inc. | 19 | $338 |
| Axsome Therapeutics, Inc. | 10 | $295 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $281 |
| Teva Pharmaceuticals USA, Inc. | 9 | $248 |
| Alkermes, Inc. | 11 | $226 |
| Lundbeck LLC | 13 | $211 |
| Neurocrine BioSciences, Inc. | 11 | $203 |
| Janssen Pharmaceuticals, Inc | 4 | $118 |
| ABBVIE INC. | 4 | $97 |
Products named: REXULTI, COBENFY, Auvelity, CAPLYTA, ARISTADA, INGREZZA, SPRAVATO, VRAYLAR.
Industry payments across NY — which companies pay providers there.
